Charlotte’s Web Holdings, Inc. Announces Board Changes: Co-Founder Jared Stanley Departs to Focus on DeFloria
Charlotte’s Web Holdings, Inc. (CWBHF), a leading producer in the hemp and CBD wellness sector, has filed a Form 8-K with the SEC announcing significant changes to its Board of Directors. The report, dated June 3, 2026 and filed June 5, 2026, confirms the departure of Mr. Jared Stanley from the Board, marking a notable transition for the company and its shareholders.
Key Points from the SEC Filing
- Board Departure: Jared Stanley, co-founder and long-serving Board member, has officially left the Board of Directors of Charlotte’s Web Holdings, Inc.
- Press Release: The company issued a press release on June 5, 2026, formally announcing Mr. Stanley’s departure and his intent to focus on DeFloria, Inc., a company pursuing clinical research and product development in cannabis therapeutics.
- No Immediate Financial Statement Impact: The filing does not indicate any changes to the company’s accounting principles or financial statement disclosures as a result of this departure.
- Emerging Growth Company Status: Charlotte’s Web continues to be classified as an “Emerging Growth Company” under SEC rules, which may affect its reporting and compliance requirements.
Potential Price-Sensitive Information for Shareholders
- Leadership Transition: The exit of a co-founder and major figure like Jared Stanley could have direct implications for investor confidence, company vision, and strategic direction. Leadership changes at the board level are often viewed as price-sensitive events, especially when they involve founders.
- Impact on Strategic Partnerships: The press release notes that Mr. Stanley will be focusing on DeFloria, Inc., and references ongoing relationships between Charlotte’s Web and DeFloria. Any changes or continuation in this relationship—particularly regarding clinical trials, therapeutic efficacy, or regulatory developments—could materially affect Charlotte’s Web’s future prospects.
- Regulatory Environment: The company highlights expectations regarding future regulatory changes, including the anticipated reclassification of cannabis to Schedule III. If realized, such regulatory shifts may open new markets or alter compliance costs and risks, potentially impacting valuation.
- Forward-Looking Statements: The company provides a detailed caution about forward-looking statements, emphasizing risks around regulatory changes, product development, supply chains, talent retention, and market acceptance. Investors should be aware that actual outcomes may differ significantly from management’s projections.
Details of the Departure and Related Events
The press release attached to the SEC filing states that Jared Stanley’s departure is to allow him to devote greater attention to DeFloria, Inc., which is working on new clinical trials and product development, including the AJA001 oral solution. The release further mentions the ongoing relationship between Charlotte’s Web and DeFloria, suggesting possible future collaborations or shared research outcomes.
Management underscores that future results—such as clinical trial outcomes, regulatory approvals, or continued collaboration—could materially differ from current expectations. The risks cited include supply chain disruptions, loss of key customers or retail partners, share price volatility, loss of proprietary information, and regulatory uncertainty.
Corporate Governance and Officer Information
- The report is signed by Mindy Garrison, Chief Commercial Officer and Corporate Secretary, on behalf of Charlotte’s Web Holdings, Inc.
- The company’s principal executive office remains at 700 Tech Court, Louisville, CO 80027, with contact available through its investor relations team.
Implications for Investors
The departure of Jared Stanley from the Board is a significant event for Charlotte’s Web Holdings, Inc. Shareholders should monitor subsequent announcements regarding board composition, leadership succession, and ongoing partnerships with DeFloria. The company’s outlook may be affected by developments in clinical research, product innovation, and regulatory changes in the cannabis sector, all of which could influence share price volatility and long-term value.
Disclaimer: This article is based on information provided in Charlotte’s Web Holdings, Inc.’s SEC filing and associated press release as of June 5, 2026. The content is for informational purposes only and does not constitute investment advice. Forward-looking statements involve significant risks and uncertainties. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
